Dose and side effects of sublingual misoprostol for treatment of postpartum hemorrhage: what difference do they make?

Wilfrido León, Jill Durocher, Gustavo Barrera, Ernesto Pinto, Beverly Winikoff, Wilfrido León, Jill Durocher, Gustavo Barrera, Ernesto Pinto, Beverly Winikoff

Abstract

Background: Shivering and fever are common side effects of misoprostol. An unexpectedly high rate of fever above 40°C was documented among Ecuadorian women given treatment with 800mcg of sublingual misoprostol to manage postpartum hemorrhage (PPH) (36%). Much lower rates have been reported elsewhere (0-9%).

Methods: From February to July 2010, an open-label pilot study was conducted in Quito, Ecuador to determine whether a lower dose--600mcg sublingual misoprostol--would result in a lower incidence of high fever (≥40°C). Rates of shivering and fever with 600mcg sublingual regimen were compared to previously documented rates in Ecuador following PPH treatment with 800mcg sublingual misoprostol.

Results: The 600mcg dose resulted in a 55% lower rate of high fever compared with the 800mcg regimen (8/50; 16% vs. 58/163; 36%; relative risk 0.45 95% CI 0.23-0.88). Only one woman had severe shivering following the 600mcg dose compared with 19 women in the 800mcg cohort (2% vs. 12%; relative risk 0.17 (0.02-1.25)). No cases of delirium/altered sensorium were reported with the 600mcg dose and women's assessment of severity/tolerability of shivering and fever was better with the lower dose.

Conclusions: 600mcg sublingual misoprostol was found to decrease the occurrence of high fever among Ecuadorian women when given to treat PPH. This study however was not powered to examine the efficacy of this treatment regimen and cannot be recommended at this time. Future research is needed to confirm whether other populations, outside of Quito, Ecuador, experience unusually high rates of elevated body temperature following sublingual administration of misoprostol for treatment of PPH. If indeed similar trends are found elsewhere, larger trials to confirm the efficacy of lower dosages may be justified.

Trial registration: Clinical trials.gov, Registry No. NCT01080846.

Figures

Figure 1
Figure 1
Average temperature trends for cases with high fever following 600 mcg (n=8) and 800mcg (n=58) doses of misoprostol for PPH treatment.

References

    1. Blum J, Winikoff B, Raghavan S, Dabash R, Ramadan MC, Dilbaz B, Dao B, Durocher J, Yalvac S, Diop A. et al.Treatment of post-partum haemorrhage with sublingual misoprostol versus oxytocin in women receiving prophylactic oxytocin: a double-blind, randomised, non-inferiority trial. Lancet. 2010;375(9710):217–223. doi: 10.1016/S0140-6736(09)61923-1.
    1. Winikoff B, Dabash R, Durocher J, Darwish E, Nguyen TN, Leon W, Raghavan S, Medhat I, Huynh TK, Barrera G. et al.Treatment of post-partum haemorrhage with sublingual misoprostol versus oxytocin in women not exposed to oxytocin during labour: a double-blind, randomised, non-inferiority trial. Lancet. 2010;375(9710):210–216. doi: 10.1016/S0140-6736(09)61924-3.
    1. Hofmeyr GJ, Gulmezoglu AM. Misoprostol for the prevention and treatment of postpartum haemorrhage. Best Pract Res Clin Obstet Gynaecol. 2008;22(6):1025–1041. doi: 10.1016/j.bpobgyn.2008.08.005.
    1. Lumbiganon P, Hofmeyr J, Gulmezoglu AM, Pinol A, Villar J. Misoprostol dose-related shivering and pyrexia in the third stage of labour. WHO Collaborative Trial of Misoprostol in the Management of the Third Stage of Labour. Br J Obstet Gynaecol. 1999;106(4):304–308. doi: 10.1111/j.1471-0528.1999.tb08266.x.
    1. Khan R-U, El-Refaey H. Pharmacokinetics and Adverse-Effect Profile of Rectally Administered Misoprostol in the Third Stage of Labor. Obstet Gynecol. 2003;101(5):968–974. doi: 10.1016/S0029-7844(03)00174-1.
    1. Chong YS, Chua S, Shen L, Arulkumaran S. Does the route of administration of misoprostol make a difference? The uterotonic effect and side effects of misoprostol given by different routes after vaginal delivery. Eur J Obstet Gynecol Reprod Biol. 2004;113(2):191–198. doi: 10.1016/j.ejogrb.2003.09.011.
    1. Tang OS, Gemzell-Danielsson K, Ho PC. Misoprostol: pharmacokinetic profiles, effects on the uterus and side-effects. Int J Gynaecol Obstet. 2007;99(Suppl 2):S160–167.
    1. Chong YS, Chua S, Arulkumaran S. Severe hyperthermia following oral misoprostol in the immediate postpartum period. Obstet Gynecol. 1997;90(4 Pt 2):703–704.
    1. Gulmezoglu AM, Villar J, Ngoc NT, Piaggio G, Carroli G, Adetoro L, Abdel-Aleem H, Cheng L, Hofmeyr G, Lumbiganon P. et al.WHO multicentre randomised trial of misoprostol in the management of the third stage of labour. Lancet. 2001;358(9283):689–695. doi: 10.1016/S0140-6736(01)05835-4.
    1. Ng PS, Chan AS, Sin WK, Tang LC, Cheung KB, Yuen PM. A multicentre randomized controlled trial of oral misoprostol and i.m. syntometrine in the management of the third stage of labour. Hum Reprod. 2001;16(1):31–35. doi: 10.1093/humrep/16.1.31.
    1. Hofmeyr GJ, Ferreira S, Nikodem VC, Mangesi L, Singata M, Jaffa Z, Maholwana B, Mlokoti Z, Walraven G, Gülmezoglu AM. Misoprostol for treating postpartum haemorrhage: a randomized controlled trial [ISRCTN72263357] BioMed Central Pregnancy and Childbirth. 2004;4(16):1–7.
    1. Zuberi NF, Durocher J, Sikander R, Baber N, Blum J, Walraven G. Misoprostol in addition to routine treatment of postpartum hemorrhage: a hospital-based randomized-controlled trial in Karachi. Pakistan. BMC Pregnancy Childbirth. 2008;8:40. doi: 10.1186/1471-2393-8-40.
    1. Widmer M, Blum J, Hofmeyr GJ, Carroli G, Abdel-Aleem H, Lumbiganon P, Nguyen TN, Wojdyla D, Thinkhamrop J, Singata M. et al.Misoprostol as an adjunct to standard uterotonics for treatment of post-partum haemorrhage: a multicentre, double-blind randomised trial. Lancet. 2010;375(9728):1808–1813. doi: 10.1016/S0140-6736(10)60348-0.
    1. Durocher J, Bynum J, Leon W, Barrera G, Winikoff B. High fever following postpartum administration of sublingual misoprostol. Bjog. 2010;117(7):845–852. doi: 10.1111/j.1471-0528.2010.02564.x.
    1. Alfirevic Z, Blum J, Walraven G, Weeks A, Winikoff B. Prevention of postpartum hemorrhage with misoprostol. International Journal of Gynaecology and Obstetrics. 2007;99(Supplement 2):S198–201.
    1. Soltan MH, El-Gendi E, Imam HH, Fathi O. Different Doses of Sublingual Misoprostol versus Methylergometrine for the Prevention of Atonic Postpartum Haemorrhage. Int J Health Sci (Qassim) 2007;1(2):229–236.
    1. Elati A, Elmahaishi MS, Elmahaishi MO, Elsraiti OA, Weeks AD. The effect of misoprostol on postpartum contractions: a randomised comparison of three sublingual doses. BJOG. 2011;118(4):466–473. doi: 10.1111/j.1471-0528.2010.02821.x.
    1. Lam H, Tang OS, Lee CP, Ho PC. A pilot-randomized comparison of sublingual misoprostol with syntometrine on the blood loss in third stage of labor. Acta Obstetricia et Gynecologica Scandinavica. 2004;83(7):647–650.
    1. Høj L, Cardoso P, Nielsen BB, Hvidman L, Nielsen J, Aaby P. Effect of sublingual misoprostol on severe postpartum haemorrhage in a primary health centre in Guinea-Bissau: randomised double blind clinical trial. BMJ: British Medical Journal. 2005;331(7519):723–727. doi: 10.1136/bmj.331.7519.723.
    1. Al-Harazi AH, Frass KA. Sublingual misoprostol for the prevention of postpartum hemorrhage. Saudi Med J. 2009;30(7):912–916.
    1. Singh G, Radhakrishnan G, Guleria K. Comparison of sublingual misoprostol, intravenous oxytocin, and intravenous methylergometrine in active management of the third stage of labor. International Journal of Gynecology & Obstetrics. 2009;107(2):130. doi: 10.1016/j.ijgo.2009.06.007.
    1. Lumbiganon P, Villar J, Piaggio G, Gulmezoglu AM, Adetoro L, Carroli G. Side effects of oral misoprostol during the first 24 hours after administration in the third stage of labour. British Journal of Obstetrics and Gynaecology. 2002;109(11):1222–1226. doi: 10.1046/j.1471-0528.2002.t01-1-02019.x.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit